<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976076</url>
  </required_header>
  <id_info>
    <org_study_id>CL-0101-WS01</org_study_id>
    <nct_id>NCT03976076</nct_id>
  </id_info>
  <brief_title>A Study of Orally Administered JBPOS0101 in Refractory Infantile Spasms Patients</brief_title>
  <official_title>A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bio-Pharm Solutions Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bio-Pharm Solutions Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open label, multicenter study allows JBPOS0101 (investigational product) to be given as&#xD;
      either add-on therapy or monotherapy for patients with refractory infantile spasms. The&#xD;
      design and choice of study population of this Phase 2 clinical study is based on the need to&#xD;
      provide initial safety, tolerability, pharmacokinetics (PK), and efficacy outcomes of the&#xD;
      investigational product for future clinical studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients will receive the investigational product at a dose of 6 mg/kg orally twice daily; once in the morning and 12 hours following the morning dose during the first 7 days of Treatment Period 1. Starting from the PM dose on the day of Visit 3, the dose will be escalated and patients will receive the investigational product at a dose of 9 mg/kg orally twice daily. Starting on Day 15, the dose will be escalated again and patients will receive the investigational product at a dose of 15 mg/kg orally twice daily until the end of Treatment Period 1.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment emergent adverse events observed by the investigator at each visit or reported to the investigator</measure>
    <time_frame>77 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Refractory Infantile Spasms</condition>
  <arm_group>
    <arm_group_label>JBPOS0101 (investigational product)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JBPOS0101</intervention_name>
    <description>JBPOS0101 (investigational product)</description>
    <arm_group_label>JBPOS0101 (investigational product)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female between 6 months through 36 months of age at the time of informed&#xD;
             consent&#xD;
&#xD;
          -  Has clinical diagnosis of IS, confirmed by video-electroencephalogram (EEG) analysis,&#xD;
             and hypsarrhythmia on EEG at screening according to the Burden of Amplitudes and&#xD;
             Epileptiform Discharges (BASED) scale score.&#xD;
&#xD;
          -  As assessed by the investigator has no or partial response to at least 2 out of the 3&#xD;
             therapies of adrenocorticotrophic hormone (ACTH), vigabatrin, and glucocorticoids&#xD;
             (i.e. prednisolone), or has no or partial response to at least 1 out of the 3&#xD;
             therapies of ACTH, vigabatrin, and glucocorticoids and is contraindicated to and/or&#xD;
             refused by the patient's legal representative(s) for treatment with one or both other&#xD;
             2 therapies.&#xD;
&#xD;
          -  Patient has general good health (defined as the absence of any clinically relevant&#xD;
             abnormalities as determined by the investigator) based on physical and neurological&#xD;
             examinations, medical history, normal renal function and electrocardiogram (ECG), and&#xD;
             clinical laboratory values completed during the Screening Period visit (Visit 1).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient considered by the investigator, for any reason (including, but not limited to,&#xD;
             the risks described as precautions and warnings in the current version of the&#xD;
             investigator's brochure for investigational product) to be an unsuitable candidate to&#xD;
             receive the investigational product.&#xD;
&#xD;
          -  Patient has known or suspected allergy to the investigational product or apple juice.&#xD;
&#xD;
          -  Patient has clinically significant renal impairment, defined as creatinine &gt;1.5 mg/dL&#xD;
             or blood urea nitrogen &gt;2 × upper limit of normal (ULN); clinically significant liver&#xD;
             dysfunction, defined as total bilirubin ≥2 × ULN, or aspartate aminotransferase or&#xD;
             alanine aminotransferase ≥3 × ULN; has clinically significant abnormal laboratory&#xD;
             values; the investigator may deem the patient eligible if he/she judges the laboratory&#xD;
             values to be not clinically significant.&#xD;
&#xD;
          -  Patient has an ongoing or known history of human immunodeficiency virus infection, or&#xD;
             chronic hepatitis B or C.&#xD;
&#xD;
          -  Patient has a clinically significant abnormality on ECG that, in the opinion of the&#xD;
             investigator, increases the safety risks of participating in the study.&#xD;
&#xD;
          -  Patient has a neurodegenerative disorder as the underlying cause of IS.&#xD;
&#xD;
          -  Patient has a known history of aspiration pneumonia within the past year.&#xD;
&#xD;
          -  Patient has previously participated in another clinical study of the investigational&#xD;
             product or received any investigational drug or device or investigational therapy&#xD;
             within 30 days of study entry.&#xD;
&#xD;
          -  Patient has received therapy with felbamate, cannabinoids, ketogenic diet or vagus&#xD;
             nerve stimulation within 14 days of screening.&#xD;
&#xD;
          -  Patient has received therapy with a medication known to be a CYP3A4 substrate and&#xD;
             whose PK has been shown to be impacted in the presence of a CYP3A4 inhibitor within 14&#xD;
             days of screening.&#xD;
&#xD;
          -  Patient has not remained at stables doses of all drugs used for treating epileptic&#xD;
             seizures for at least 14 days prior to screening (except for rescue medications used&#xD;
             for acute treatment of breakthrough seizures which are not known to be CYP3A4&#xD;
             substrates and whose PK has not been shown to be impacted in the presence of a CYP3A4&#xD;
             inhibitor.&#xD;
&#xD;
          -  Patient has a lethal or potentially lethal condition other than infantile spasms, with&#xD;
             a significant risk of death before 18 months of age such as non-ketotic&#xD;
             hyperglycinemia.&#xD;
&#xD;
          -  Patient has a body weight below 5 kg.&#xD;
&#xD;
          -  Patient has an underlying metabolic disease associated with glucose intolerance (e.g.,&#xD;
             glucose transporter deficiencies).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brandon Choi</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor Management</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brandon Choi</last_name>
    <phone>973-224-0567</phone>
    <email>bchoi@b-psol.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Wood</last_name>
    <phone>720-504-9454</phone>
    <email>scott.wood@iconplc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arkansas Children's Hospital</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Hummel</last_name>
      <phone>501-364-2715</phone>
      <email>hummelkathy@uams.edu</email>
    </contact>
    <investigator>
      <last_name>Freedom Perkins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital LA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Arellano-Garcia</last_name>
      <email>margarcia@chla.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Wendy Mitchell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA - David Geffen School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruby Escalante</last_name>
      <phone>310-206-5586</phone>
      <email>rubyescalante@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Shaun Hussain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCSF Epilepsy Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94158-2549</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoinette Swanson</last_name>
      <phone>415-502-1921</phone>
      <email>Antoinette.Swanson@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Galen Resler</last_name>
      <phone>720-777-0738</phone>
      <email>Galen.resler@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Charuta Joshi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pediatric Neurology, PA</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Carr</last_name>
      <phone>407-293-1122</phone>
      <phone_ext>221</phone_ext>
      <email>kcarr@pediatricneurologypa.com</email>
    </contact>
    <investigator>
      <last_name>Ronald Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville School of Medicine</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pediatric Research Unit</last_name>
      <phone>502-629-5820</phone>
      <phone_ext>2</phone_ext>
      <email>kcpcru@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Vinay Puri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bridget Neja</last_name>
      <phone>507-266-9150</phone>
      <email>Neja.Bridget@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Nickels, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Cornett</last_name>
      <phone>919-684-1143</phone>
      <email>k.cornett@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Muhammad Zafar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Honglian Huang</last_name>
      <phone>216-445-2366</phone>
    </contact>
    <contact_backup>
      <last_name>Xiaoming Zhang</last_name>
      <phone>216-445-7510</phone>
    </contact_backup>
    <investigator>
      <last_name>Deepak Lachhwani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beata Dyar</last_name>
      <phone>503-494-8216</phone>
      <email>dyar@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Jason Coryell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia (CHOP)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Chambers</last_name>
      <phone>215-590-1719</phone>
      <email>ChambersEM@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Eric Marsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francis Oyih</last_name>
      <phone>832-826-5961</phone>
      <email>fxoyih@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Krystal Sully, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn O'Hara</last_name>
      <phone>804-828-3862</phone>
      <email>kathryn.ohara@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Lawrence Morton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Multicare Institute for Research and Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amber Hecker-Johnson</last_name>
      <phone>253-403-9350</phone>
      <email>aheckerjohnson@multicare.org</email>
    </contact>
    <investigator>
      <last_name>Steven Phillips, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 31, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>March 3, 2021</last_update_submitted>
  <last_update_submitted_qc>March 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Spasms, Infantile</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

